Steve Grossman Explored How New U.S. Policies May Transform Hemophilia Surveillance, Safety Monitoring, and Global Data Transparency
World Federation of Hemophilia (WFH) shared a post on LinkedIn:
“Day 1 of the WFH Global Forum in Montreal brought together global experts, patients, and advocates to tackle some of the most pressing issues in bleeding disorders treatment and access.
The day opened with a critical look at policy and data. Steve Grossman explored how new U.S. policies may transform hemophilia surveillance, safety monitoring, and global data transparency—setting the stage for two days of meaningful dialogue.
In the afternoon, Ekawat Suwantaroj delivered a powerful testimony on rebalancing agents, shedding light on the significant access barriers faced by people in low- and middle-income countries. His message underscored the urgent need for equity in care.
The Forum concluded with a powerful debate on access and sustainability. WFH VP Medical, Glenn Pierce and Irish Haemophilia Society CEO, Brian O Mahony, shared global perspectives on whether universal access to all treatment options is achievable—or sustainable—in the pursuit of Treatment For All.
Stay tuned for more updates from Day 2 of the WFH Global Forum.”

Stay updated with Hemostasis Today.
-
Aug 24, 2026, 18:13Chokri Ben Lamine: Ruxolitinib – Comprehensive Clinical Reference
-
Aug 24, 2026, 18:10Yazan Abou-Ismail: ClotCast Episode 8 – What Are Platelets?
-
Aug 24, 2026, 17:11Kristin Neves: Which Hematologic Parameters Guide Your PV Treatment Decisions?
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada
-
Aug 24, 2026, 16:52Davide Capodanno: 10 Trials to Watch at the ESC Hot Lines
-
Aug 24, 2026, 16:48Mohd Ashhad: The Science Behind a Safe Transfusion
-
Aug 24, 2026, 16:38PCSK9i Is a Powerful Lipid-Lowering Strategy – But Is It Also Anti-Inflammatory?- JACC Journals
-
Aug 24, 2026, 16:36Alejandro González Veliz։ Does ACC/AHA Lesion Complexity Still Matter?
-
Aug 24, 2026, 16:21Kamlesh Darji: Paraneoplastic Syndromes – Tumor with or without Mediator